<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MEPERIDINE HYDROCHLORIDE- meperidine hydrochloride injection </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
<h1></h1>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-f719f46c-cd38-4e4c-9430-b927c9c06831"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><a name="INV-daae5ce5-5b01-422a-806c-dfedec483f64"></a><span class="Bold">CII</span></p>
<p><a name="INV-8bca714f-8147-4bad-8380-85b60be80816"></a><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="INV-a79ce8ba-6691-4bea-9042-d1aff88e6d0d"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="INV-da8838db-5576-4003-9c56-f07d2d9c9234"></a>Meperidine
                            Hydrochloride Injection, USP is a sterile solution for intramuscular,
                            subcutaneous or slow intravenous use as a narcotic analgesic.</p>
<p><a name="INV-55e7542d-b8b2-4f3b-b360-621a7bb8e6ef"></a>Each mL of the
                            DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75
                            mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium
                            acetate. pH 3.5-6.0.</p>
<p><a name="INV-c1900837-d197-4643-a889-97926ed38e89"></a>Meperidine
                            hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a
                            white crystalline substance with a melting point of
                            186°-189°C. It is readily soluble in water and has a
                            slightly bitter taste. Its structural formula is as follows:</p>
<div class="Figure">
<img alt="" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=987a91b8-dd9e-47ce-bd43-f8189a54838e&amp;name=Meperidine.jpg"><p class="MultiMediaCaption">C<span class="Sub">15</span>H<span class="Sub">21</span>NO<span class="Sub">2</span>•HCl      MW
                                283.79</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="INV-6ebbb696-bc4b-4946-9115-f486e8dcac36"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><a name="INV-5f056ba5-226e-497d-adfe-bd5a78167f74"></a>Meperidine
                            hydrochloride is a narcotic analgesic with multiple actions
                            qualitatively similar to those of morphine; the most prominent of these
                            involve the central nervous system and organs composed of smooth muscle.
                            The principal actions of therapeutic value are <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and sedation.</p>
<p><a name="INV-2ec923ec-179a-4039-b301-6ae5859f4d2a"></a>There is some
                            evidence which suggests that meperidine may produce less smooth muscle
                            spasm, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex than
                            equianalgesic doses of morphine. Meperidine, in 60 to 80 mg parenteral
                            doses, is approximately equivalent in <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> to 10 mg of
                            morphine. The onset of action is slightly more rapid than with morphine,
                            and the duration of action is slightly shorter. Meperidine is
                            significantly less effective by the oral than by the parenteral route,
                            but the exact ratio of oral to parenteral effectiveness is unknown.</p>
<p><a name="INV-2fdc3d71-5b26-4bf4-938f-2f23ff12fc27"></a>In clinical
                            studies, changes in several pharmacokinetic parameters with increasing
                            age have been observed. The initial volume of distribution and
                            steady-state volume of distribution may be higher in elderly patients
                            than in younger patients.<span class="Sup">1</span> The free fraction of meperidine in
                            plasma may be higher in patients over 45 years of age than in younger
                                patients.<span class="Sup">2</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INV-36289069-db63-4df8-b874-f8ffc37a6d54"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="INV-58c954f9-4c68-4f7c-9368-ad9ac22913be"></a>For the relief of
                            moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><a name="INV-59b020a9-9259-419b-a436-e3b953cea10d"></a>For preoperative
                            medication.</p>
<p><a name="INV-171a0f9d-e766-44b1-90b2-e086a8e891c5"></a>For support of
                            anesthesia.</p>
<p><a name="INV-5630ef06-530f-4556-9056-7bf715323cc4"></a>For obstetrical
                            <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="INV-eb5db7f5-f637-4233-95e4-852546e87580"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="INV-56bd02d7-9145-4168-a0a8-b40e03534ae1"></a><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to
                            meperidine.</p>
<p><a name="INV-b3d0b2e9-f62a-484c-93d9-689453b70bf1"></a>Meperidine is
                            contraindicated in patients who are receiving monoamine oxidase (MAO)
                            inhibitors or those who have recently received such agents. Therapeutic
                            doses of meperidine have occasionally precipitated unpredictable, severe
                            and occasionally fatal reactions in patients who have received such
                            agents within 14 days. The mechanism of these reactions is unclear, but
                            may be related to a preexisting hyperphenylalaninemia. Some have been
                            characterized by <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, severe <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> and
                            <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and have resembled the syndrome of acute narcotic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
                            In other reactions, the predominant manifestations have been
                            <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> and
                            <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Although it is not known that other narcotics are free of
                            the risk of such reactions, virtually all of the reported reactions have
                            occurred with meperidine. If a narcotic is needed in such patients, a
                            sensitivity test should be performed in which repeated, small,
                            incremental doses of morphine are administered over the course of
                            several hours while the patient’s condition and vital signs
                            are under careful observation. (Intravenous hydrocortisone or
                            prednisolone have been used to treat severe reactions, with the addition
                            of intravenous chlorpromazine in those cases exhibiting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and
                            <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>. The usefulness and safety of narcotic antagonists in the
                            treatment of these reactions is unknown.)</p>
<p><a name="INV-c5ed89e1-8b97-4674-984b-c2b36426553a"></a>Solutions of
                            meperidine hydrochloride and barbiturates are chemically
                        incompatible.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="INV-4969abee-291c-4e49-a5f3-ad3cea5a10f8"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42227-9">
<a name="INV-66ccfbcd-816c-4226-b311-38506811f94d"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></h2>
<p class="First"><a name="INV-dddecc61-19d4-418a-a054-a4b105eab659"></a>Meperidine
                                    can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and therefore
                                    has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical
                                    <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance may develop upon repeated
                                    administration of meperidine. It should be prescribed and
                                    administered with the same degree of caution appropriate to the
                                    use of morphine. Like other narcotics, meperidine is subject to
                                    the provisions of the Federal narcotic laws.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-6b1e3b18-34a9-4985-b347-9e6a4c6fa63a"></a><a name="section-7.2"></a><p></p>
<h2>Interaction with
                                Other Central Nervous System Depressants</h2>
<p class="First"><a name="INV-f853287a-8dc3-4b2f-8f38-727e2caae47e"></a>MEPERIDINE
                                    SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN
                                    PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC
                                    ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER
                                    TRANQUILIZERS (SEE <a href="#INV-beb977cc-8222-4aff-abe2-38701467d351">DOSAGE AND
                                        ADMINISTRATION</a>), SEDATIVEHYPNOTICS (INCLUDING
                                    BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS
                                    DEPRESSANTS (INCLUDING ALCOHOL). <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>,
                                    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">HYPOTENSION</span> AND PROFOUND SEDATION OR <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">COMA</span> MAY
                                RESULT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-c43efecc-db95-4fd1-b458-5ef735ba8613"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and
                                <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First"><a name="INV-5b6568b8-04ec-4994-914c-e6399e6a7227"></a>The
                                    respiratory depressant effects of meperidine and its capacity to
                                    elevate cerebrospinal fluid pressure may be markedly exaggerated
                                    in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions or a
                                    preexisting increase in intracranial pressure. Furthermore,
                                    narcotics produce adverse reactions which may obscure the
                                    clinical course of patients with head injuries. In such
                                    patients, meperidine must be used with extreme caution and only
                                    if its use is deemed essential.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-711a4196-3489-419c-b7b6-0b27a4c652c4"></a><a name="section-7.4"></a><p></p>
<h2>Intravenous Use</h2>
<p class="First"><a name="INV-64efaaa8-fb11-4601-882a-03222f2e29ff"></a>If
                                    necessary, meperidine may be given intravenously, but the
                                    injection should be given very slowly, preferably in the form of
                                    a diluted solution. Rapid intravenous injection of narcotic
                                    analgesics, including meperidine, increases the incidence of
                                    adverse reactions; severe <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>,
                                    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, peripheral <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>
                                    have occurred. Meperidine should not be administered
                                    intravenously unless a narcotic antagonist and the facilities
                                    for assisted or controlled respiration are immediately
                                    available. When meperidine is given parenterally, especially
                                    intravenously, the patient should be lying down.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-4652f1f1-f7da-4e92-81f5-e2257c8e1e34"></a><a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> and Other
                                Respiratory Conditions</h2>
<p class="First"><a name="INV-59419472-5a88-4cdb-9f6e-a274940e3dca"></a>Meperidine
                                    should be used with extreme caution in patients having an acute
                                    <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic attack</span>, patients with chronic obstructive pulmonary
                                    disease or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, patients having a substantially
                                    decreased respiratory reserve and patients with preexisting
                                    <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>. In such
                                    patients, even usual therapeutic doses of narcotics may decrease
                                    respiratory drive while simultaneously increasing airway
                                    resistance to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-87b703bf-289d-463e-bde5-03d92af87071"></a><a name="section-7.6"></a><p></p>
<h2>Hypotensive Effect</h2>
<p class="First"><a name="INV-0e17b082-99ef-4c4c-9a86-18316a114ac9"></a>The
                                    administration of meperidine may result in severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in
                                    the postoperative patient or any individual whose ability to
                                    maintain blood pressure has already been compromised by a
                                    depleted blood volume or administration of drugs, such as the
                                    phenothiazines or certain anesthetics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-ceba2719-1ec1-4847-832c-a9e387ad4f0b"></a><a name="section-7.7"></a><p></p>
<h2>Usage in Ambulatory
                                Patients</h2>
<p class="First"><a name="INV-1c2048cc-ae64-4851-93d1-2a0cfe1d37e7"></a>Meperidine
                                    may impair the mental and/or physical abilities required for the
                                    performance of potentially hazardous tasks such as driving a car
                                    or operating machinery. The patient should be cautioned
                                    accordingly.</p>
<p><a name="INV-7df41185-eccb-49d2-a76d-8cb667d3f4a1"></a>Meperidine,
                                    like other narcotics, may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in
                                    ambulatory patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-05620a3a-d8dd-4612-a276-e91fbb30b981"></a><a name="section-7.8"></a><p></p>
<h2>Usage in Pregnancy
                                and Lactation</h2>
<p class="First"><a name="INV-298ce028-77fb-4483-9e26-05e79aba9396"></a>Meperidine
                                    should not be used in pregnant women prior to the labor period,
                                    unless in the judgment of the physician the potential benefits
                                    outweigh the possible hazards, because safe use in pregnancy
                                    prior to labor has not been established relative to possible
                                    adverse effects on fetal development.</p>
<p><a name="INV-f402ecf0-12f1-4ae6-b5f4-d42483731b6b"></a>When used
                                    as an obstetrical analgesic, meperidine crosses the placental
                                    barrier and can produce <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of respiration and
                                    psychophysiologic functions in the newborn. Resuscitation may be
                                    required (see section on <a href="#INV-6f04d6cc-3309-419b-a05c-0d9950219cb0">OVERDOSAGE</a>).</p>
<p><a name="INV-5207b38a-fdca-4493-bf85-d27fc6a88981"></a>Meperidine
                                    appears in the milk of nursing mothers receiving the
                                drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="INV-292597b4-03fb-484a-ae9e-6512832c45b2"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><a name="INV-36e0fa26-c741-47d0-b8a0-5119dcca64fe"></a>As with all
                            intramuscular preparations, meperidine intramuscular injection should be
                            injected well within the body of a large muscle.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-f87cd866-ef65-4d01-a4ec-4eca5ddf4951"></a><a name="section-8.1"></a><p></p>
<h2>Supraventricular
                                <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardias</span></h2>
<p class="First"><a name="INV-75b80ae7-c384-495e-98f4-aa0d3b6f0de8"></a>Meperidine
                                    should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> and
                                    other <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardias</span> because of a possible
                                    vagolytic action which may produce a significant increase in the
                                    ventricular response rate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-dd8c2190-4496-4e82-90b1-b5ade778420c"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></h2>
<p class="First"><a name="INV-05bb3e4b-9893-44ed-bb4b-1e154ae04d85"></a>Meperidine
                                    may aggravate preexisting <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with
                                    <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>. If dosage is escalated substantially above
                                    recommended levels because of tolerance development, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>
                                    may occur in individuals without a history of convulsive
                                    disorders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-cb783615-5b40-462b-8273-d8ee2357446d"></a><a name="section-8.3"></a><p></p>
<h2>Acute Abdominal
                                Conditions</h2>
<p class="First"><a name="INV-7758e69b-7310-435f-9070-16255a1c4a68"></a>The
                                    administration of meperidine or other narcotics may obscure the
                                    diagnosis or clinical course in patients with acute abdominal
                                    conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-83fceb7d-3013-4110-acf2-ff1374dbfd5f"></a><a name="section-8.4"></a><p></p>
<h2>Special Risk
                                Patients</h2>
<p class="First"><a name="INV-9e864133-7998-45bc-9227-6a47b9831c91"></a>Meperidine
                                    should be given with caution and the initial dose should be
                                    reduced in certain patients such as the elderly or debilitated
                                    and those with severe impairment of hepatic or renal function,
                                    <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, Addison’s disease and prostatic
                                    <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="INV-0374e0d9-2500-4617-8733-44e5e696a81e"></a><a name="section-8.5"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First"><a name="INV-09ec91c0-4fd3-4e99-89f6-99c0490c5f0c"></a>Clinical
                                    studies of meperidine did not include sufficient numbers of
                                    subjects aged 65 and over to determine whether they respond
                                    differently from younger subjects. Other reported clinical
                                    experience has not identified differences in response between
                                    the elderly and younger patients. In general, dose selection for
                                    an elderly patient should be low, usually starting at the low
                                    end of the dosing range, reflecting the greater frequency of
                                    decreased hepatic, renal, or cardiac function, and of
                                    concomitant disease or other drug therapy. Doses of meperidine
                                    should be reduced in elderly patients. (See <a href="#INV-beb977cc-8222-4aff-abe2-38701467d351">DOSAGE AND
                                        ADMINISTRATION</a>.)</p>
<p><a name="INV-979ddc03-8579-4031-a6d0-906715b5f68a"></a>Sedating
                                    drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and oversedation in the elderly;
                                    elderly patients generally should be started on low doses of
                                    meperidine and observed closely.</p>
<p><a name="INV-31b262df-489d-4d30-b304-39ccff2c0ec9"></a>This drug
                                    is known to be substantially excreted by the kidney, and the
                                    risk of toxic reactions to this drug may be greater in patients
                                    with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more
                                    likely to have decreased renal function, care should be taken in
                                    dose selection, and it may be useful to monitor renal function.</p>
<p><a name="INV-b7da0ef9-108d-4aae-bc48-7d6e0ca8b297"></a>Clinical
                                    studies indicate that differences in various pharmacokinetic
                                    parameters may exist between elderly and younger patients. (See
                                        <a href="#INV-6ebbb696-bc4b-4946-9115-f486e8dcac36">CLINICAL
                                        PHARMACOLOGY</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="INV-5c4cdb0d-4160-478b-8936-ab78d3dc72a6"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><a name="INV-ec6a809b-4932-4ea4-b2c5-473bb00e2032"></a>The major hazards
                            of meperidine, as with other narcotic analgesics, are respiratory
                            <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and, to a lesser degree, circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; respiratory
                            arrest, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred.</p>
<p><a name="INV-fa56c494-ae62-4b84-8d26-73b4fb1e3f3a"></a>The most frequently
                            observed adverse reactions include <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation,
                            <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. These effects seem to be more prominent
                            in ambulatory patients and in those who are not experiencing severe
                            <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. In such individuals, lower doses are advisable. Some adverse
                            reactions in ambulatory patients may be alleviated if the patient lies
                            down. Other adverse reactions include:</p>
<p><a name="INV-ca862597-7bb0-4807-a1e5-e2c8d19dfcee"></a><span class="Bold">Central Nervous System</span>-<span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoria</span>,
                            <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, uncoordinated muscle
                            movements, severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, transient <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and
                            <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>. Inadvertent injection about a nerve
                            trunk may result in sensory-motor <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> which is usually, though not
                            always, transitory.</p>
<p><a name="INV-b250d7d9-5f7f-4a3d-bd95-1fb2be7991ae"></a><span class="Bold">Gastrointestinal</span>-<span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>,
                            biliary tract spasm.</p>
<p><a name="INV-499526bd-04d3-4f95-b944-11e47b6e937a"></a><span class="Bold">Cardiovascular</span>-<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> of the face,
                            <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (see <a href="#INV-4969abee-291c-4e49-a5f3-ad3cea5a10f8">WARNINGS</a>), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> following intravenous
                            injection.</p>
<p><a name="INV-1e5bd9e4-f663-4a80-9af9-4890bdba4123"></a><span class="Bold">Genitourinary</span>-<span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>.</p>
<p><a name="INV-dec93c2f-3ce5-4b91-9545-1d7c5ed8a49a"></a><span class="Bold">Allergic</span>-<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, other skin
                            <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, wheal and flare over the vein with IV injection.</p>
<p><a name="INV-90c2e8fe-8ea0-4e67-9e2c-c62e8f2556e2"></a><span class="Bold">Other</span>-<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at injection site; local
                            tissue irritation and <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> following subcutaneous injection,
                            particularly when repeated; antidiuretic effect.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="INV-6f04d6cc-3309-419b-a05c-0d9950219cb0"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-29d014c9-3f41-4dd7-8a9a-87db48c9f296"></a><a name="section-10.1"></a><p></p>
<h2>Symptoms</h2>
<p class="First"><a name="INV-287f71cd-cc6c-4c88-823e-c449f240baa6"></a>Serious
                                    <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with meperidine is characterized by respiratory
                                    <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume,
                                    Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>
                                    progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>
                                    and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In
                                    severe overdosage, particularly by the intravenous route, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>,
                                    <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may
                                occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-6a9611e5-8a4c-44e7-a543-33328e8b4163"></a><a name="section-10.2"></a><p></p>
<h2>Treatment</h2>
<p class="First"><a name="INV-883d3e63-5fc6-4d30-b8c4-7f2183f15618"></a>Primary
                                    attention should be given to the reestablishment of adequate
                                    respiratory exchange through provision of a patent airway and
                                    institution of assisted or controlled ventilation. The narcotic
                                    antagonist naloxone hydrochloride is a specific antidote against
                                    <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or
                                    unusual sensitivity to narcotics, including meperidine.
                                    Therefore, an appropriate dose of naloxone hydrochloride should
                                    be administered, preferably by the intravenous route,
                                    simultaneously with efforts at respiratory resuscitation.</p>
<p><a name="INV-60d7b538-a680-4557-8d96-4bfb36cd48e7"></a>An
                                    antagonist should not be administered in the absence of
                                    clinically significant respiratory or cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.
                                    Oxygen, intravenous fluids, vasopressors and other supportive
                                    measures should be employed as indicated.</p>
<p><a name="INV-9eb557bb-e5e0-438f-ad01-135d9e4caaf3"></a>NOTE: In an
                                    individual physically dependent on narcotics, the administration
                                    of the usual dose of a narcotic antagonist will precipitate an
                                    acute withdrawal syndrome. The severity of this syndrome will
                                    depend on the degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and the dose of
                                    antagonist administered. The use of narcotic antagonists in such
                                    individuals should be avoided if possible. If a narcotic
                                    antagonist must be used to treat serious <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>
                                    in the physically dependent patient, the antagonist should be
                                    administered with extreme care and only one-fifth to one-tenth
                                    the usual initial dose administered.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="INV-beb977cc-8222-4aff-abe2-38701467d351"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-3c1a8e94-968d-49ba-acdc-aaa9e7f7efb9"></a><a name="section-11.1"></a><p></p>
<h2>For Relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></h2>
<p class="First"><a name="INV-fad7ae02-d905-4d44-89ed-06aec0409272"></a>Dosage
                                    should be adjusted according to the severity of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and the
                                    response of the patient. While subcutaneous administration is
                                    suitable for occasional use, intramuscular administration is
                                    preferred when repeated doses are required. If intravenous
                                    administration is required, dosage should be decreased and the
                                    injection made very slowly, preferably utilizing a diluted
                                    solution. Meperidine is less effective orally than by parenteral
                                    administration. The dose of meperidine should be proportionately
                                    reduced (usually by 25 to 50 percent) when administered
                                    concomitantly with phenothiazines and many other tranquilizers
                                    since they potentiate the action of meperidine.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-b7a1a1c4-e556-45fd-998b-f4fe7695558c"></a><a name="section-11.1.1"></a><p></p>
<h3>Adults</h3>
<p class="First"><a name="INV-6791403e-748f-44b1-b2b7-c986574c1f28"></a>The
                                            usual dosage is 50 to 150 mg intramuscularly or
                                            subcutaneously every 3 to 4 hours as necessary. Elderly
                                            patients should usually be given meperidine at the lower
                                            end of the dose range and observed closely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-397189e8-4294-41b1-83fb-4ec50ee3805b"></a><a name="section-11.1.2"></a><p></p>
<h3>Children</h3>
<p class="First"><a name="INV-9754811f-0544-48ff-b3fd-d113e638393f"></a>The
                                            usual dosage is 0.5 to 0.8 mg/lb intramuscularly or
                                            subcutaneously up to the adult dose, every 3 to 4 hours                                            as necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-3b7406dc-bef8-4713-8fb5-fbf22fd46189"></a><a name="section-11.2"></a><p></p>
<h2>For Preoperative
                                Medication</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-c492a07f-e598-42ad-8224-258daa5f94a2"></a><a name="section-11.2.1"></a><p></p>
<h3>Adults</h3>
<p class="First"><a name="INV-ebc2b034-1633-447c-97bf-6e58b411cb20"></a>The
                                            usual dosage is 50 to 150 mg intramuscularly or
                                            subcutaneously every 3 to 4 hours as necessary. Elderly
                                            patients should usually be given meperidine at the lower
                                            end of the dose range and observed closely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-aeaf06ea-47a7-481d-afee-f004a5902f9d"></a><a name="section-11.2.2"></a><p></p>
<h3>Children</h3>
<p class="First"><a name="INV-cdbd1e1b-48d8-440b-a6fc-b9cc4f881310"></a>The
                                            usual dosage is 0.5 to 1 mg/lb intramuscularly or
                                            subcutaneously up to the adult dose, 30 to 90 minutes
                                            before the beginning of anesthesia.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-618782ac-e070-4c8d-bc29-87bdae43fd51"></a><a name="section-11.3"></a><p></p>
<h2>For Support of
                                Anesthesia</h2>
<p class="First"><a name="INV-941d85fe-9097-4fd1-93af-fc6eba23edd3"></a>Repeated
                                    slow intravenous injections of fractional doses (e.g., 10 mg/mL)
                                    or by a continuous intravenous infusion of a more dilute
                                    solution (e.g., 1 mg/mL) should be used. The dose should be
                                    titrated to the needs of the patient and will depend on the
                                    premedication and type of anesthesia being employed, the
                                    characteristics of the particular patient and the nature and
                                    duration of the operative procedure. Elderly patients should
                                    usually be given meperidine at the lower end of the dose range
                                    and observed closely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INV-9283f599-9ea0-434d-84c9-f3c54e9292ae"></a><a name="section-11.4"></a><p></p>
<h2>For Obstetrical
                                <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></h2>
<p class="First"><a name="INV-4a201879-20ea-496c-a3ab-26d8a0ac6430"></a>The usual
                                    dosage is 50 to 100 mg intramuscularly or subcutaneously when
                                    <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> becomes regular and may be repeated at 1 to 3 hour
                                    intervals.</p>
<p><a name="INV-47592a4f-f730-4952-8bbb-cbaa580fc930"></a><span class="Bold">Parenteral drug products should be
                                        inspected visually for particulate matter and discoloration
                                        prior to administration, whenever solution and container
                                        permit.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="INV-73043b8c-80af-498b-8d7e-9af21b348914"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="INV-5976456d-7a23-4716-89b7-ed70ae7680d4"></a>Meperidine
                            Hydrochloride Injection, USP is available in the following packages:</p>
<p><a name="INV-96d1fcb9-8574-4f59-836d-9444e19e1d13"></a>25 mg/mL</p>
<p><a name="INV-648e6832-bf03-4f95-ab5e-cfa319318c35"></a>1 mL DOSETTE vials
                            packaged in 25s ( <span class="Italics">NDC</span>10019-159-01)</p>
<p><a name="INV-c064e113-08c5-40d2-8c58-d375c17b13bd"></a>50 mg/mL</p>
<p><a name="INV-a654c8cf-b049-45e5-a75b-e27e2c342e38"></a>1 mL DOSETTE vials
                            packaged in 25s ( <span class="Italics">NDC</span>10019-160-01)</p>
<p><a name="INV-fe5777a3-de7a-447b-acec-37be4a12b1a8"></a>75 mg/mL</p>
<p><a name="INV-eafa7efb-3b39-4b2a-905b-05be81b32b5b"></a>1 mL DOSETTE vials
                            packaged in 25s ( <span class="Italics">NDC</span>10019-161-01)</p>
<p><a name="INV-72755115-b291-4fd4-b296-2d8e9e7082e1"></a>100 mg/mL</p>
<p><a name="INV-dad939ba-59bb-475e-94d5-822bd7b7eb73"></a>1 mL DOSETTE vials
                            packaged in 25s ( <span class="Italics">NDC</span>10019-162-01)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="INV-0e125a45-f2a4-41ec-8174-185c9b74b295"></a><a name="section-12.1"></a><p></p>
<h2>Storage</h2>
<p class="First"><a name="INV-22deec3f-a59d-4660-b555-e1fd9fa23cdf"></a><span class="Bold">Store at 20°-25°C
                                        (68°-77°F), excursions permitted to
                                        15°-30°C (59°-86°F) [see
                                        USP Controlled Room Temperature].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="INV-03dfa17a-762c-49d3-a08e-203a716d6edb"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"><a name="INV-e2e38703-866e-4dc8-ad27-a23a0498b244"></a>1. Mather, LE et
                            al: Meperidine kinetics in man. Intravenous injection in surgical
                            patients and volunteers. <span class="Italics">Clin Pharmacol
                                Ther</span> 17:21-30, 1975.</p>
<p><a name="INV-eac1a46b-4bc9-46e2-8096-9cd089219289"></a>2. Herman, RJ et
                            al: Effects of age on meperidine disposition. <span class="Italics">Clin Pharmacol Ther</span> 37:19-24, 1985.</p>
<p><a name="INV-a070ef01-b77e-4583-8717-b60a61a9762e"></a>Baxter and Dosette
                            are trademarks of Baxter International Inc., or its subsidiaries.</p>
<p><a name="INV-26c03f19-ba16-4e85-901b-03e0c582e836"></a>Manufactured by</p>
<p><a name="INV-d283fb61-fecb-4ce8-831f-9473439978ec"></a><span class="Bold">Baxter Healthcare Corporation</span></p>
<p><a name="INV-999cf7cf-62dc-405e-b1cb-5660c7895359"></a>Deerfield, IL 60015
                            USA</p>
<p><a name="INV-469cd864-3bb5-43e7-adfe-7e75c2f641ac"></a>For Product Inquiry
                            1 800 ANA DRUG (1-800-262-3784)</p>
<p><a name="INV-30582f00-994d-4334-b522-150a5b2ee8ae"></a>MLT-01168/3.0</p>
<p><a name="INV-cb0aca1d-0964-470a-9c8c-ccbf47f2b6fc"></a></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MEPERIDINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">meperidine hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-159</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Meperidine Hydrochloride</strong> (Meperidine) </td>
<td class="formItem"></td>
<td class="formItem">25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acetic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium acetate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-159-01</td>
<td class="formItem">25  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-159-44</td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MEPERIDINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">meperidine hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-160</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Meperidine Hydrochloride</strong> (Meperidine) </td>
<td class="formItem"></td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acetic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium acetate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-160-01</td>
<td class="formItem">25  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-160-44</td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MEPERIDINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">meperidine hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-161</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Meperidine Hydrochloride</strong> (Meperidine) </td>
<td class="formItem"></td>
<td class="formItem">75 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acetic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium acetate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-161-01</td>
<td class="formItem">25  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-161-44</td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MEPERIDINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">meperidine hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-162</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Meperidine Hydrochloride</strong> (Meperidine) </td>
<td class="formItem"></td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acetic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium acetate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-162-01</td>
<td class="formItem">25  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-162-44</td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6F01FA95-C389-9E12-3626-0AD38904DA09</div>
<div>Set id: 987a91b8-dd9e-47ce-bd43-f8189a54838e</div>
<div>Version: 1</div>
<div>Effective Time: 20080307</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
